Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
about
DPP4 in DiabetesDPP-4 inhibition and islet functionEfficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extensionTargeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistanceDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.Practical Application of Antidiabetic Efficacy of Lycium barbarum Polysaccharide in Patients with Type 2 Diabetes.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision studyIncretin-based therapies: new treatments for type 2 diabetes in the new millennium.Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialExercise therapy in type 2 diabetes.Vildagliptin in clinical practice: a review of literature.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.The alpha-cell as target for type 2 diabetes therapy.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.Do we know the true mechanism of action of the DPP-4 inhibitors?C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor TherapyEffects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.Assessment of beta-cell function in young patients with type 2 diabetes: arginine-stimulated insulin secretion may reflect beta-cell reserve.Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice.Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.
P2860
Q26797335-60C51E1E-1D85-4630-B9E8-5E17D59D7E8EQ27028127-48C4433B-6146-43A4-9DDC-AEDB95A32F9EQ33626226-E60A8BEF-5D97-43B1-A416-A76172D1C7BAQ34004470-64B8990B-E752-478E-8CEE-510C389C6F73Q35026483-31B1C85C-8A48-4B8D-B203-51E850D6355DQ35091620-518F4A35-6ACB-4630-89EF-173A54E899DBQ35763816-8CBC5E26-4333-4987-AE82-0D5E0E9262F2Q35928257-2CA067D8-2FF0-498D-B9AB-CE2F30BDCA06Q36628919-258B20DB-EC89-4C62-8ECB-03A048E2AE78Q36758200-983F2914-F486-4C18-9A7F-F9FCF90F8625Q36960161-E7DE9E49-17E5-450A-B084-C3BF2D39BF92Q37153711-E9947CFE-9950-42E6-B9E9-998F55864BB0Q37316259-BDC6C6BA-0723-48AC-90AF-4CE40515B9A9Q37348976-5DD4187F-0378-4E38-BBDF-EFED4F1C47AFQ37412024-DBDEAF7E-74DE-47A7-996B-D3D0354110F5Q37623831-307E99DB-1C6F-4724-91ED-DF4542D89DF1Q37652091-70E9CD1D-DAF1-455E-8141-8C2960CE81E8Q37867193-2A783767-EBB2-495F-9EE4-49040655017AQ37900151-D8E2A0ED-7FC5-4D0D-8A53-D8B6C1BB1EFAQ37900690-8A8F8163-7AA9-4702-AC54-BF716918E85DQ37977335-25862CFA-B5B6-4490-B66E-E55D2987FCFEQ37984567-5EEDFC6A-94C4-4B88-A383-032E7AEEEADBQ38106411-D6765BB4-32EE-4512-A0AD-C7235BC9BC52Q38682317-C41476C9-EA54-4F03-B3DF-99D3174BB3D2Q39329866-C43E87F6-2A7F-451E-8DF7-82F46675AF81Q42368200-7C701A22-3642-4EF2-9005-A16F3B726244Q45985301-2E83F73D-28BF-4053-B46B-5B20A322DEA8Q49991307-6AACA914-09AE-429A-B231-65258474AC87Q51327644-65476FAB-AB83-4158-8070-437D84BA8E25Q51349530-7D1E2ACF-5D6C-4220-ACFC-CAB3258C18F5Q51377185-ED247868-4E21-4037-8374-D63AB1B5CC72Q51381989-43756FAB-BB90-498D-A9F3-3070817722DFQ55397117-20B49CF7-D2D9-47A4-8D17-B3CEA41D05D4
P2860
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@en
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@nl
type
label
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@en
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@nl
prefLabel
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@en
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@nl
P2093
P2860
P356
P1476
Treatment with the dipeptidyl ...... subjects with type 2 diabetes.
@en
P2093
Amanda M Denney
Beth E Dunning
David A D'Alessio
James E Foley
Julie M Martin
Linda M Hermiller
Monica Liqueros Saylan
Richard E Pratley
Ronald L Prigeon
William G Tharp
P2860
P356
10.1210/JC.2008-1135
P407
P577
2008-10-28T00:00:00Z